Biostar Pharmaceuticals appoints independent director | S&P Global Market Intelligence

Workflow Solutions
Products
See more S&P Global Solutions
See More IHS Markit Solutions
Content
How We Can Help
See More
News & Insights Topics
See More
Featured Events
Webinar ReplaysNew Corporate Realities: Blending Geopolitics, Data, and Digital Transformation
- 07/21/2022
- On-Demand
- 1 Hour
In PersonInteract 2022
- 09/15/2022
- 225 Liberty Street, New York, New York
- 225 Liberty Street
In Person451Nexus
- 10/03/2022
- ARIA Resort and Casino, Las Vegas, Nevada
Platforms
Other Products
- Leveraged Commentary and Data
- Research Online

Biostar Pharmaceuticals appoints independent director

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Global M&A by the Numbers: Q2 2022

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Infographic 2022 Top Tech Trends Shaping Corporations

28 Dec, 2017 | 16:52

Biostar Pharmaceuticals appoints independent director

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

Biostar Pharmaceuticals Inc. appointed Melissa Fan Chen as independent director after the departure of Leung King Fai.

Chen has worked at West Park Capital, a FINRA registered broker/dealer and investment banking firm, since September 2016.